Compare BZFD & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZFD | RNTX |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | United States |
| Employees | N/A | 11 |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 30.0M |
| IPO Year | N/A | N/A |
| Metric | BZFD | RNTX |
|---|---|---|
| Price | $0.60 | $1.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 208.1K | 83.0K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.69 | N/A |
| Revenue Next Year | $108.06 | N/A |
| P/E Ratio | $292.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $1.02 |
| 52 Week High | $2.68 | $2.22 |
| Indicator | BZFD | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.05 | 45.92 |
| Support Level | N/A | $1.08 |
| Resistance Level | $0.84 | $1.30 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 27.50 | 27.78 |
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.